Pacira BioSciences: The FDA and SEC Found the Exparel Maker Promoted Its Long-Acting Anesthetic for Uses Not Approved on Its Label

Pacira BioSciences Inc., the Parsippany, New Jersey pharmaceutical company that commercializes Exparel — a liposomal bupivacaine formulation providing extended-duration local anesthesia for surgical pain management — faced enforcement scrutiny from both the Food and Drug Administration over promotional activities for Exparel that exceeded the drug's approved label indications and from the Securities and Exchange Commission over whether the company's investor disclosures accurately characterized the regulatory risk those promotional activities created for the company's primary revenue-generating product.DOCUMENTED

The Pacira case illustrated the dual regulatory exposure that pharmaceutical companies face when off-label promotion practices generate both FDA enforcement attention for the promotional conduct itself and SEC scrutiny for the adequacy of investor disclosures about the regulatory risk — a disclosure issue that arises when promotional activities that could generate FDA enforcement are not accurately characterized in the risk disclosures that investors rely on to assess the company's regulatory position.

Exparel and Its Approved Indications

Exparel is a formulation of bupivacaine — a commonly used local anesthetic — encapsulated in liposomes that release the drug slowly over time, providing analgesia for up to 72 hours following surgical procedures. The drug received FDA approval for single-dose infiltration to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block for shoulder surgery pain. These specific approved indications represent the evidence base the FDA reviewed when approving the drug — clinical trials demonstrating safety and efficacy for the specific uses, at the specific doses and administration routes studied.REVIEWED

Pacira's commercial success with Exparel depended on broad adoption across surgical specialties and procedures beyond the specifically studied indications, and the company's sales force and promotional materials had, according to the FDA, communicated about the drug's benefits in contexts beyond the approved label — including procedures and nerve block applications for which the FDA had not reviewed efficacy and safety data through its formal approval process. The FDA's concern with off-label promotion is that it creates the impression that a drug's use is supported by the same regulatory review process that the approved indications reflect, when the off-label use has not been evaluated through that process and may have different safety and efficacy characteristics than the approved uses.DOCUMENTED

The FDA Warning Letter

The FDA's Warning Letter to Pacira documented specific promotional communications — including detail pieces provided to prescribers by Pacira's sales force and content on the company's website — that the agency found promoted Exparel for uses beyond its approved indications. The Warning Letter required Pacira to immediately cease the identified off-label promotional activities and to submit a corrective action plan demonstrating how the company would bring its promotional practices into compliance with the approved label. FDA Warning Letters for off-label promotion are public documents that signal the agency's conclusion that the identified promotional conduct violated the Food, Drug, and Cosmetic Act's prohibition on misbranded drug promotion — and they create a clear public record of the regulatory concern that is relevant to investor assessment of the company's regulatory risk position.REVIEWED

The practical regulatory consequences of sustained off-label promotion extend beyond the Warning Letter itself: if Exparel was promoted for and used in off-label applications that were then billed to Medicare and Medicaid, the promotional conduct creates potential False Claims Act exposure, because federal health programs generally cover drugs only for FDA-approved indications or for uses supported by specific compendia. Off-label promotion that drives off-label prescribing that is then billed to federal health programs can constitute a knowing and willful contribution to false claims — which has been the basis for major False Claims Act settlements against pharmaceutical companies in the past.

A Warning Letter from the FDA about off-label promotion is not a technical citation. For a company whose entire revenue depends on one drug, it is a signal that the commercial strategy has run ahead of the regulatory approval — and investors are entitled to know that.

The SEC's Disclosure Scrutiny

The SEC's parallel scrutiny of Pacira's investor disclosures focused on whether the company had adequately characterized the regulatory risk created by its promotional practices in the risk factor disclosures and MD&A sections of its public filings. A company that is engaged in promotional activities that the FDA could characterize as off-label promotion has a known regulatory risk that is material if it could result in enforcement consequences — including Warning Letters, consent decrees, or False Claims Act liability — that would affect the company's commercial operations or financial results. The question the SEC examined was whether Pacira's disclosures about this risk were specific and accurate enough to give investors a materially complete picture of the risk, rather than characterizing off-label promotion risk in generic boilerplate language that did not reflect the specific promotional practices the company was actually engaged in.DOCUMENTED

Pharmaceutical company disclosure of FDA regulatory risk has been a recurring SEC enforcement focus, because the gap between the FDA enforcement risk a company's promotional practices create and the risk disclosure language in its SEC filings can be material — particularly for companies like Pacira, where a single product represents the substantial majority of revenue and where any FDA enforcement action that affected that product's commercial activities would have significant financial consequences. The SEC's position is that company-specific regulatory risk requires company-specific disclosure language, not just inclusion of the risk in a list of generic pharmaceutical sector risks that apply equally to all companies in the industry regardless of their specific practices.

Compliance Lessons for Pharmaceutical Promotion

The Pacira case illustrates the compliance framework that pharmaceutical companies must maintain to avoid off-label promotion violations: training of sales force personnel on approved indication boundaries, review and approval of promotional materials by medical, legal, and regulatory functions before use, monitoring of sales force communications and materials for content that exceeds label claims, and clear policies distinguishing between permissible scientific exchange and impermissible promotional communication. Companies that invest in robust promotional compliance programs — including field force monitoring and disciplinary consequences for off-label communication — reduce both the risk of FDA Warning Letters and the potential False Claims Act exposure that follows when off-label promotion drives off-label prescribing in government-paid settings. The cost of building and maintaining these compliance programs is substantially lower than the enforcement, litigation, and reputational consequences of the alternative.

Have documents relevant to this story? Reach us through our tips channel.